A5057319982- Advanced Radiotherapy Techniques
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging Techniques and Applications
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Radiation Therapy and Dosimetry
- Colorectal Cancer Surgical Treatments
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Effects of Radiation Exposure
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Screening and Detection
- Gene expression and cancer classification
- Urologic and reproductive health conditions
- Esophageal Cancer Research and Treatment
- Colorectal Cancer Treatments and Studies
- AI in cancer detection
- Hormonal and reproductive studies
- MRI in cancer diagnosis
University College London
2022-2025
Royal Marsden Hospital
2019-2024
Institute of Cancer Research
2018-2024
Royal Marsden NHS Foundation Trust
2018-2024
University College London Hospitals NHS Foundation Trust
2022-2024
Royal London Hospital
2022
The University of Melbourne
2018
Sisters of Mercy Health System
2018
The Christie NHS Foundation Trust
2015-2016
Stony Brook University
2004-2013
BackgroundLocalised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute toxicity compared conventionally fractionated or moderately hypofractionated We report the findings from a randomised trial of standard-of-care versus five-fraction for low-risk intermediate-risk...
4006 Background: Locoregional treatments for inoperable, non-metastatic CC remain undefined. Single arm phase 2 data suggested that SBRT may improve clinical outcomes. We aimed to investigate the efficacy and safety of addition with CisGem in locally advanced inoperable CC. Methods: ABC-07 (ISRCTN:10639376) is a II multicentre randomized trial patients histologically confirmed CC, WHO performance status 0-1. After registration showing no progression after 4 cycles were (2:1) treatment...
With increasing incorporation of MRI in radiotherapy, we investigate two sequences for prostate delineation radiographer-led image guidance.
PurposeThe CHHiP trial randomized 3216 men with localized prostate cancer (1:1:1) to 3 radiation therapy fractionation schedules: 74 Gy in 37 fractions over 7.4 weeks; 60 20 4 and 57 19 3.8 weeks. Literature-based dose constraints were applied arithmetic adjustment for the hypofractionated arms. This study aimed derive anorectal using prospectively collected clinician-reported outcomes (CROs) patient-reported (PROs) assess added predictive value of spatial metrics.Methods MaterialsA...
Intraprostatic fiducial markers (FM) improve the accuracy of radiotherapy (RT) delivery. Here we assess geometric integrity and contouring consistency using a T2*-weighted (T2*W) sequence alone, which allows visualization FM.Ten patients scanned within Prostate Advances in Comparative Evidence (PACE) trial (NCT01584258) had prostate images acquired with computed tomography (CT) Magnetic Resonance (MR) Imaging: T2-weighted (T2W) T2*W sequences. The was contoured independently on each imaging...
Changes in fraction size of external beam radiation therapy exert nonlinear effects on subsequent toxicity. Commonly described by the linear-quadratic model, sensitivity normal tissues is expressed α/β ratio. We sought to study individual ratios for different late rectal after prostate therapy.
Moderately hypofractionated external beam intensity modulated radiation therapy (RT) for prostate cancer is now standard-of-care. Normal tissue toxicity responses to fraction size alteration are nonlinear: the linear-quadratic model a widely used framework accounting this, through α/β ratio. Few ratio estimates exist human late genitourinary endpoints; here we provide derived from hypofractionation trial.
Several studies have demonstrated the association between acute and late radiotherapy toxicity in prostate cancer using older techniques. However, whether this is present with newer techniques such as stereotactic body (SBRT), remains unclear. We use univariable multivariable logistic regression to analyse grade 2 or worse gastrointestinal (GI) genitourinary (GU) toxicities equivalent patients treated SBRT conventional moderately fractionated (CRT) within PACE-B study. 842 were included...
1 Background: External beam radiotherapy (EBRT) is a curative treatment for LPCa. Large randomised controlled trials (RCTs) have shown moderately hypofractionated regimens (2.5–3 Gy/fraction(f)) as non-inferior to conventionally fractionated (2 Gy/f). PACE-B aims demonstrate non-inferiority of SBRT compared CFMHRT biochemical or clinical failure. Compared CFMHRT, reduces patient (pt) attendances but compressed overall time may influence acute toxicity severity. Methods: PACE phase III...
PurposeThe urethra is a critical structure in prostate radiotherapy planning; however, it impossible to visualise on CT. We developed surrogate model (SUM) for CT-only planning workflow and tested its geometric dosimetric performance against the MRI-delineated (MDU).MethodsThe SUM was compared 34 different MDUs (within treatment PTV) patients treated with 36.25 Gy (PTV)/40 (CTV) 5 fractions as part of PACE-B trial. To assess surrogate's performance, Dice similarity coefficient (DSC),...